血清维生素D水平及添加治疗对多发性硬化患者预后的影响

发布时间：2018-05-26 19:08

本文选题：血清维生素D水平 + -羟维生素D_　；参考：《实用医学杂志》2017年05期

【摘要】：目的:评估多发性硬化(MS)患者与正常健康人群体内血清25-羟维生素D3[25-(OH)D_3]水平,以及添加1,25-羟维生素D3[1,25-(OH)2D_3,骨化三醇]口服对于MS预防复发和疾病进展的关系。方法:缓解复发型多发性硬化(RRMS)患者组60例和健康组68例,评估统计两组性别、年龄、25-(OH)D_3水平的差异。同时将60例MS患者随机分成激素治疗组和添加治疗组,每组30例,添加治疗组在激素治疗组的基础上添加骨化三醇胶丸口服,在治疗6、12、24个月后对两组进行EDSS分值评估,在24个月后统计复发次数以及复发时间间隔。结果:患者组与健康组血清25-(OH)D_3水平分别为(18.75±8.35)nmol/L和(23.28±9.31)nmol/L,差异有显著统计学意义。治疗后激素治疗组与添加治疗组在复发次数(P0.01)、复发时间间隔(P0.05)、EDSS分值(24月后)(P0.05),具有统计学差异,而EDSS分值(6个月后)(P=0.457)、EDSS分值(12个月后)(P=0.118)两组间比较差异无统计学意义。结论:MS患者血清25-(OH)D_3水平显著低于正常健康人群。添加骨化三醇有助于防治MS复发,延长复发时间间隔,维持较长时间口服有助于延缓疾病残疾进展。
[Abstract]:Objective: to evaluate the serum levels of 25-hydroxyvitamin D _ 3 [25-(OH)D_3] in patients with multiple sclerosis (MS) and healthy controls, and the relationship between oral administration of 1-O25-hydroxyvitamin D3 (OH2D3) and oral administration of ossifying triol (OH2D3) in the prevention of relapse and progression of disease in patients with multiple sclerosis (MS). Methods: 60 patients with relapsed multiple sclerosis (RRMS) and 68 healthy controls were enrolled in this study. At the same time, 60 patients with MS were randomly divided into hormone treatment group (n = 30) and adjunctive treatment group (n = 30). In addition to hormone treatment group (n = 30), the treatment group received oral administration of oscitic triol gel pill, and the EDSS scores of the two groups were evaluated after treatment for 612,24 months. The number of recurrence and the interval of recurrence were calculated after 24 months. Results: the serum 25-(OH)D_3 levels in patients and healthy subjects were 18.75 卤8.35)nmol/L and 23.28 卤9.31 nmol / L, respectively. After treatment, there was statistical difference between the hormone treatment group and the admixture treatment group in the number of relapse (P 0.01), the interval between the two groups (P 0.05%) (24 months later), but the EDSS score (6 months later) was not significantly different between the two groups (P 0.118 after 12 months), and there was no significant difference between the two groups in the frequency of recurrence (P 0.01) and the interval between the two groups (P 0. 05%, P 0. 05) after 24 months (P 0. 05%, P 0. 05%), but there was no significant difference between the two groups. Conclusion the serum 25-(OH)D_3 level in patients with MS was significantly lower than that in normal controls. The addition of ossifying triol can help to prevent the recurrence of MS, prolong the interval of relapse, and maintain a long oral period to delay the progression of the disease.
【作者单位】：广州总医院脑病医疗中心;广州总医院干部病房;杭州疗养院神经科;
【基金】：广东省医学科学技术研究基金(编号:A2014487)
【分类号】：R744.51

【相似文献】